Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study
Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study
复制标题
DOI：
10.5301/ejo.2010.1405
复制
发表时间：
2011-05-01
影响因子：
1.7
通讯作者：
Malihi, Mehrdad
中科院分区：
文献类型：
--
作者：
Fard, Masoud Aghsaei;Abyane, Alireza Yazdanei;Malihi, Mehrdad
目的。目的探讨白内障手术时玻璃体腔内注射贝伐单抗对糖尿病视网膜病变患者术后视网膜增厚的影响。患者被随机分为两组，一组接受标准化的超声乳化联合人工晶状体植入术(对照组，30只眼)，另一组在手术结束时接受1.25 mg的贝伐单抗(IVB组，31只眼)。疗效测量包括最佳矫正视力(BCVA)测试，光学相干断层扫描(OCT)，以及术后6个月每次随访时的眼底镜检查。对照组和IVB组的中心黄斑厚度、BCVA或全身状况在基线时没有显著差异。术后1个月，对照组黄斑中心厚度显著增加，而贝伐单抗组黄斑中心厚度无明显增加。6个月后，两组黄斑厚度和术后视力差异无统计学意义。白内障手术时玻璃体腔内注射1.25 mg贝伐单抗仅在短期内有效，6个月的结果与对照组相同。
Purpose. To determine the role of intravitreal bevacizumab injected at the time of cataract surgery on postoperative increase of retinal thickness in patients with diabetic retinopathy.Methods. Patients were randomized to a standardized procedure of phacoemulsification with intraocular lens implantation alone (control group; 30 eyes) or to receive 1.25 mg intravitreal bevacizumab at the end of surgery (IVB group; 31 eyes). Efficacy measures included best-corrected visual acuity (BCVA) testing, optical coherence tomography (OCT), and ophthalmoscopic examination at each postoperative visit during a 6-month follow-up.Results. There were no significant differences in central macular thickness, BCVA, or systemic condition between the control and IVB groups at baseline. One month after surgery, the control group showed a significant increase in central macular thickness, whereas the bevacizumab group did not show an increase. After 6 months, there was no significant difference in macular thickness and postoperative visual acuity between the 2 groups.Conclusions. Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery is effective just for the short term and 6-month results are the same as the control group.